Cargando…
Reovirus in cancer therapy: an evidence-based review
Reovirus, a double-stranded ribonucleic acid virus and benign human pathogen, preferentially infects and kills cancer cells in its unmodified form, and is one of the leading oncolytic viruses currently undergoing clinical trials internationally. With 32 clinical trials completed or ongoing thus far,...
Autores principales: | Clements, Derek, Helson, Erin, Gujar, Shashi A, Lee, Patrick WK |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918368/ https://www.ncbi.nlm.nih.gov/pubmed/27512664 http://dx.doi.org/10.2147/OV.S51321 |
Ejemplares similares
-
Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy
por: Kumar, Vishnupriyan, et al.
Publicado: (2021) -
Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014) -
Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
por: Gujar, Shashi A, et al.
Publicado: (2014) -
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
por: Kim, Youra, et al.
Publicado: (2015) -
Activation of p53 by Chemotherapeutic Agents Enhances Reovirus Oncolysis
por: Pan, Da, et al.
Publicado: (2013)